Regulatory | ApexOnco - Clinical Trials news and analysis

“The team is super responsive to my inquiries and suggestions”

Chief Business Officer

US public biotech company

Click here for more information

Regulatory

17 December 2024

FDA knocks back subcutaneous Rybrevant

Regulatory

16 December 2024

Checkpoint's latecomer could draw interest

Regulatory

5 December 2024

Merus bags its first approval

Data insights Regulatory

3 December 2024

FDA red and green lights: November 2024

Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.

Regulatory

28 November 2024

Kelun hits dato-dxd while it's down

Regulatory

27 November 2024

Cabometyx’s Cabinet committee

Regulatory

27 November 2024

EU backs Tevimbra's stomach restriction – and then some

Regulatory

22 November 2024

Targeted lung cancer niche sees a German pharma battle

But could toxicity be holding back filing plans?

Regulatory

19 November 2024

Jefferies 2024 – Arvinas gets a degrader delay

Regulatory

19 November 2024

Jefferies 2024 – Nuvation lays out its US taletrectinib strategy

Subscribe to Regulatory

FDA knocks back subcutaneous Rybrevant

Checkpoint's latecomer could draw interest

Merus bags its first approval

FDA red and green lights: November 2024

Kelun hits dato-dxd while it's down

Cabometyx’s Cabinet committee

EU backs Tevimbra's stomach restriction – and then some

Targeted lung cancer niche sees a German pharma battle

Jefferies 2024 – Arvinas gets a degrader delay

Jefferies 2024 – Nuvation lays out its US taletrectinib strategy

Recent Quick take

Most Popular